GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market Challenges
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
Medscape2d
Maternal Hepatitis C Virus Infection Linked to Increased NICU Admissions and SGA Births
The study highlighted that 57.7% of neonates in the case group had a diagnosis of neonatal abstinence syndrome compared to 10 ...
yourlifechoices.com.au7h
Shingles vaccine access expanded
Access to the free shingles vaccine has been expanded to all immunocompromised people aged 18 and over. But experts fear that ...
STAT6d
Millions of Americans want to quit smoking. Critics say drugmakers and the FDA are failing them
There hasn’t been a new class of drugs approved to help smokers quit since Pfizer's Chantix reached the market nearly two ...
Another Mistrial in Zantac: Fourth Illinois Jury Fails to Award Damages
On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...
LancasterOnline3d
GSK expansion project in East Donegal Township could get a tax break
East Donegal Township is considering a tax break that would benefit an expansion of the GSK vaccine packaging facility in ...
Critical Mass With Law.com's Amanda Bronstad: Johnson & Johnson Files Third Talc Bankruptcy, Zantac Mistrial Gives Plaintiffs Their Fourth Loss
In this month's trial, which began on Aug. 28, Eric Olson ( Olson Grimsley) and Ashley Keller ( Keller Postman) represented ...
Medscape9d
Best Survival Outcomes With Neoadjuvant Immunotherapy in Melanoma
Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...
Investing18d
GlaxoSmithKline hold rating reaffirmed by TD Cowen
TD Cowen maintained a Hold rating on GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), with a consistent price target of $1,790.00. The firm's stance comes after GlaxoSmithKline reported positive Phase ...